CA2107104A1 - Pyridazinone acetic acids as aldose reductase inhibitors - Google Patents

Pyridazinone acetic acids as aldose reductase inhibitors

Info

Publication number
CA2107104A1
CA2107104A1 CA002107104A CA2107104A CA2107104A1 CA 2107104 A1 CA2107104 A1 CA 2107104A1 CA 002107104 A CA002107104 A CA 002107104A CA 2107104 A CA2107104 A CA 2107104A CA 2107104 A1 CA2107104 A1 CA 2107104A1
Authority
CA
Canada
Prior art keywords
compound
methyl
hydrogen
formula
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002107104A
Other languages
English (en)
French (fr)
Inventor
Banavara L. Mylari
William J. Zembrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2107104A1 publication Critical patent/CA2107104A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002107104A 1991-03-28 1992-03-09 Pyridazinone acetic acids as aldose reductase inhibitors Abandoned CA2107104A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28
US676,919 1991-03-28

Publications (1)

Publication Number Publication Date
CA2107104A1 true CA2107104A1 (en) 1992-09-29

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107104A Abandoned CA2107104A1 (en) 1991-03-28 1992-03-09 Pyridazinone acetic acids as aldose reductase inhibitors

Country Status (19)

Country Link
EP (1) EP0582643A1 (enExample)
JP (1) JPH06500793A (enExample)
CN (1) CN1065269A (enExample)
AU (1) AU658887B2 (enExample)
BR (1) BR9205810A (enExample)
CA (1) CA2107104A1 (enExample)
CZ (1) CZ387092A3 (enExample)
DE (1) DE9290035U1 (enExample)
FI (1) FI934222A0 (enExample)
HU (1) HUT67836A (enExample)
IE (1) IE920979A1 (enExample)
IL (1) IL101325A0 (enExample)
MX (1) MX9201414A (enExample)
NZ (1) NZ242152A (enExample)
PT (1) PT100301A (enExample)
TW (1) TW207998B (enExample)
WO (1) WO1992017446A2 (enExample)
YU (1) YU30392A (enExample)
ZA (1) ZA922238B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
ATE352551T1 (de) 2001-03-30 2007-02-15 Pfizer Prod Inc Pyridazinon aldose reductase inhibitoren
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (zh) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Also Published As

Publication number Publication date
IE920979A1 (en) 1992-10-07
BR9205810A (pt) 1994-06-28
TW207998B (enExample) 1993-06-21
WO1992017446A3 (en) 1992-11-26
MX9201414A (es) 1992-10-01
YU30392A (sh) 1994-11-15
PT100301A (pt) 1993-06-30
CN1065269A (zh) 1992-10-14
FI934222L (fi) 1993-09-27
CZ387092A3 (en) 1994-02-16
NZ242152A (en) 1994-07-26
FI934222A7 (fi) 1993-09-27
WO1992017446A2 (en) 1992-10-15
ZA922238B (en) 1993-09-27
AU658887B2 (en) 1995-05-04
EP0582643A1 (en) 1994-02-16
AU1779692A (en) 1992-11-02
DE9290035U1 (de) 1993-11-18
IL101325A0 (en) 1992-11-15
FI934222A0 (fi) 1993-09-27
HU9302728D0 (en) 1993-12-28
HUT67836A (en) 1995-05-29
JPH06500793A (ja) 1994-01-27

Similar Documents

Publication Publication Date Title
EP0065392B1 (en) Pharmaceutical compositions containing spiro succinimide derivatives
US5268386A (en) Certain 3,4-dihydro 4-oxospiro [2H-1 benzopyrans] useful for treating hyperuricemia
HU198696B (en) Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
US4996204A (en) Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5304557A (en) Substituted oxoophthalazinyl acetic acids and analogs thereof
US4678786A (en) Pharmaceutical compositions having β-adrenoceptor antagonist activity employing pyridazinone derivatives
CA2107104A1 (en) Pyridazinone acetic acids as aldose reductase inhibitors
EP0266102B1 (en) Quinoxalinone derivatives
US4963689A (en) Heterocyclicguanidines as 5HT3 antagonists
AU609559B2 (en) Heterocyclic oxophthalazinyl acetic acids
EP0553130B1 (en) Pyrrolidine dione derivatives
US4457939A (en) Aldose reductase inhibiting 5-(2-alkoxy-3-substituted phenyl)hydantoins
KR860001507B1 (ko) 5-(치환된 페닐) 히단토인의 제조방법
WO1992012979A1 (en) 2,4-DIOXO-PYRIDO [2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS AND SALTS THEREOF
IE832538L (en) 5-phenylsubstituted imidazolidine-2,4-diones
EP0171213A1 (en) Spiro-imidazolones for treatment of diabetic complications
JPWO1996020186A1 (ja) カルボン酸誘導体、その製造方法及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued